内皮素-NADPH氧化酶途径和心肌钙调控蛋白:心律失常和心衰治疗药物的新靶点  

Endothelin-NADPH Oxidase Pathway and Calcium Regulatory Proteins in Myocardium:New Targets for the Treatment of Cardiac Arrhythmias and Heart Failure

作　　者：施芳红[1] 戴德哉[1] 于锋[1] 戴茵[1] 

机构地区：[1]中国药科大学药理研究室,江苏南京210009

出　　处：《药学进展》2012年第7期308-315,共8页Progress in Pharmaceutical Sciences

基　　金：国家自然科学基金项目(No.81070145)

摘　　要：心肌雷诺定受体2是一种心肌细胞钙释放通道,对心肌Ca2+循环起着至关重要的作用。该受体的功能受心肌钙调控蛋白FKBP12.6、SERCA2a和CASQ2等的影响,而此类蛋白的表达又与内皮素-NADPH氧化酶(ET-NOX)途径有关。ET-NOX途径和心肌钙调控蛋白的异常均会导致心律失常和心衰。因此,ET-NOX途径中各成员以及心肌钙调控蛋白有可能成为治疗心律失常和心衰的新靶标。综述了心肌钙调控蛋白和ET-NOX途径在正常心肌兴奋收缩耦联过程及病理过程中的作用,并介绍了相关的在研抗心律失常药物。Cardiac ryanodine receptor 2,as a Ca2＋ release channel,plays a key role in Ca2＋ circulation of myocardium.Its function is influenced by many regulatory proteins,such as FKBP12.6,SERCA2a and CASQ2,the expression of which is associated with endothelin-NADPH oxidase（ET-NOX） pathway.The abnormality of ET-NOX pathway and calcium regulatory proteins in myocardium will both lead to arrhythmias or heart failure.Therefore,the members of ET-NOX pathway and myocardial calcium regulatory proteins may provide new targets to develop promising drugs for the treatment of arrhythmias and heart failure.The role of ET-NOX pathway and myocardial calcium regulatory proteins in the normal excitation-contraction coupling process and pathological process was reviewed,as well as the related drugs for the treatment of arrhythmias in development were introduced in this paper.

关 键 词：内皮素-NADPH氧化酶途径 雷诺定受体2 钙调控蛋白 心律失常 心衰 

分 类 号：R541.6[医药卫生—心血管疾病] R541.7[医药卫生—内科学]